Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Simin Qi, Jinyun Dong, Zhiyuan Xu, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 201

Showing 1-25 of 201 citing articles:

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Marco H. Hofmann, Daniel Gerlach, Sandra Misale, et al.
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 924-937
Open Access | Times Cited: 184
An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 141
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Qian Zhong, Xina Xiao, Yijie Qiu, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 103
Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis
Semanti Mukherjee, Arunima Sakunthala, Laxmikant Gadhe, et al.
Journal of Molecular Biology (2022) Vol. 435, Iss. 1, pp. 167713-167713
Open Access | Times Cited: 81
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Xiumei Wu, Mengyun Xu, M. Geng, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 81
Targeted protein degradation: from mechanisms to clinic
Jonathan M. Tsai, Radosław P. Nowak, Benjamin L. Ebert, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 9, pp. 740-757
Closed Access | Times Cited: 77
Chemically engineering cells for precision medicine
Yixin Wang, Zhaoting Li, Fanyi Mo, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 3, pp. 1068-1102
Closed Access | Times Cited: 40
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Qing Li, Shan Geng, Hao Luo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 25
Nanoplatform-enhanced photodynamic therapy for the induction of immunogenic cell death
Xu Liu, Yichao Lu, Xiang Li, et al.
Journal of Controlled Release (2024) Vol. 365, pp. 1058-1073
Closed Access | Times Cited: 17
Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview
Xu Liu, Cheng Yang, Yao Mu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy
Popat Mohite, Vaishnavi Yadav, Ramdas Pandhare, et al.
ACS Omega (2024)
Open Access | Times Cited: 13
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 2
Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 64
Protein degradation technology: a strategic paradigm shift in drug discovery
Haobin Li, Jinyun Dong, Mao-Hua Cai, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 62
Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)
Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, et al.
Chemical Communications (2022) Vol. 58, Iss. 29, pp. 4635-4638
Closed Access | Times Cited: 40
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options
Yating Wang, Shou‐Ching Tang
Cancer and Metastasis Reviews (2022) Vol. 41, Iss. 4, pp. 975-990
Open Access | Times Cited: 37
Ubiquitin–proteasome system as a target for anticancer treatment—an update
Yeon‐Jung Kim, Yeonjoo Lee, H. Y. Shin, et al.
Archives of Pharmacal Research (2023) Vol. 46, Iss. 7, pp. 573-597
Closed Access | Times Cited: 26
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Design, synthesis and biological evaluation of KRASG12C-PROTACs
Xiaoyi Zhang, Tong Zhao, Minghao Sun, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 78, pp. 117153-117153
Closed Access | Times Cited: 24
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Jun Ma, Jack Junjie Chan, Ching Han Toh, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1700-1711
Closed Access | Times Cited: 23
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
Ritesh P. Bhole, Payal R. Kute, Rupesh V. Chikhale, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106720-106720
Closed Access | Times Cited: 22
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 22
Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top